At the time of writing, Black Diamond Therapeutics Inc [BDTX] stock is trading at $1.93, up 10.29%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BDTX shares have gain 31.74% over the last week, with a monthly amount glided 38.85%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Black Diamond Therapeutics Inc [NASDAQ: BDTX] stock has seen the most recent analyst activity on July 31, 2024, when Raymond James initiated its Outperform rating and assigned the stock a price target of $20. On June 30, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $10 on the stock. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $11 on June 28, 2023. Wedbush upgraded its rating to a Outperform but $10 remained the price target by the analyst firm on June 27, 2023. Wedbush downgraded its rating to Neutral for this stock on March 29, 2022. In a note dated March 22, 2022, H.C. Wainwright downgraded an Neutral rating on this stock.
For the past year, the stock price of Black Diamond Therapeutics Inc fluctuated between $1.20 and $6.75. Currently, Wall Street analysts expect the stock to reach $14.75 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $1.93 at the most recent close of the market. An investor can expect a potential return of 664.25% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.05 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7900 points at the first support level, and at 1.6500 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0250, and for the 2nd resistance point, it is at 2.1200.
Ratios To Look Out For
It is important to note that Black Diamond Therapeutics Inc [NASDAQ:BDTX] has a current ratio of 9.24. Further, the Quick Ratio stands at 9.24, while the Cash Ratio is 5.84. Considering the valuation of this stock, the price to sales ratio is 1.56, the price to book ratio is 0.77 and price to earnings (TTM) ratio is 31.28.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Mar 19 ’25 when 5.78 million shares were sold. 10% Owner, Versant Venture Capital VI, L. completed a deal on Aug 28 ’24 to sell 0.22 million shares. Meanwhile, Former Employer David Epstein bought 50000.0 shares on Jul 31 ’24.
